[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"aneurysm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:aneurysm":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,47,75,106,136,165,188,220,241,263,295,326,351,373,395,422],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":31,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100523693","cera-vascular-plug-system-post-market-clinical-follow-up-100523693",false,"NCT06099015","Cera™ Vascular Plug System Post-Market Clinical Follow-Up","Cera™ Vascular Plug System Post-Market Clinical Follow-Up: A Multi-center, Prospective, Observational, Single-arm, Open-label, Post-market Study","Inclusion Criteria:\n\n1. Aged 18 to 85;\n2. Life expectancy \\> 1 year;\n3. Require arterial or venous embolization in the peripheral vasculature;\n4. Target embolization site(s) allow for safe insertion of the delivery catheter;\n5. Voluntarily sign and date the Informed Consent Form (ICF) prior to any study-related activities commencement;\n6. Willing and able to comply with protocol requirements, including all study visits and procedures.\n7. Patients for whom the doctor has decided to use the Cera Vascular Plug System, regardless of the study.\n\nExclusion Criteria:\n\n1. The subject is pregnant or plan to be pregnant or breast feeding;\n2. The subject has a known allergy or hypersensitivity to any of the device materials including: nickel, stainless steel, polytetrafluoroethylene and titanium nitride;\n3. The subject has a known allergy or hypersensitivity to contrast agent;\n4. The subject has uncorrectable coagulopathy;\n5. The subject has planned use of anticoagulant (e.g. direct thrombin inhibitors, factor Xa inhibitors, vitamin K antagonists) or antiplatelet therapy before, during and\u002For after treatment with the study device, which, in the opinion of the Investigator, would clinically interfere with the study endpoints\n6. The subject has an unresolved systemic infection;\n7. Subject who cannot tolerate general or local anesthesia;\n8. The subject has a connective tissue disorders (e.g. Ehlers-Danlos Syndrome), arteritis (e.g. Takayasu's Disease) or another circulatory disorder;\n9. The subject is participating in other drug or medical device clinical trials;\n10. Any condition (medical or anatomic) making the subject not suitable for transcatheter embolotherapy according to the opinion of the investigator.","ALL","18 Years","85 Years",{"count":20,"type":21},132,"ESTIMATED","OBSERVATIONAL","The objective of the study is to collect and evaluate clinical data on patients of the Lifetech Cera™ Vascular Plug System to:\n\n* confirm the performance\n* confirm the safety\n* identify previously unknown side-effects\n* monitor the identified side-effects (related to the procedures or to the medical devices)\n* identify and analyse emergent risks",[25,26,27,28,29,30],"Aneurysm","Endoleak","Pulmonary Arteriovenous Malformation","Portal Hypertension","Arteriovenous Fistula","Splenic Laceration",[32,33],"Lifetech","Cera Vascular Plug","RECRUITING","2026-06-10",{"date":37,"type":38},"2026-06-12","ACTUAL",{"date":40,"type":38},"2024-06-21",{"date":42,"type":21},"2028-06-30",{"name":44,"class":45},"Lifetech Scientific (Shenzhen) Co., Ltd.","INDUSTRY",9,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":74},"100258086","phase-1-infliximab-therapy-for-dolichoectactic-vertebrobasilar-aneurysms-100258086","NCT02638701","Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms","Inclusion Criteria:\n\n1. Vertebral and\u002For basilar artery dolichoectactic aneurysm not amenable to microsurgical or endovascular treatment.\n2. Age greater than 18 years at time of first study drug administration.\n\nExclusion Criteria:\n\n1. Use of an anti-TNF or other biologic medication (Including but not limited to abatacept, rituximab, or tocilizumab) within the previous 12 months.\n2. The following laboratory parameters at the Screening visit: Neutropenia (absolute neutrophil count \\\u003C 1,500\u002Fmicroliter; Thrombocytopenia (platelets \\\u003C 100,000\u002F • Anemia (hemoglobin \\\u003C 8 g\u002FdL); Greater than or equal to 3 times the upper limit of normal (ULN) for either of the following liver function tests (LFTs): aspartate transaminase (AST) or alanine transaminase (ALT); Renal insufficiency (serum creatinine\\> 2.0 mg\u002FdL)\n3. Purified protein derivative (PPD) test of \\> 5 mm induration regardless of prior BacilleCalmette Guerin vaccine administration or positive QuantiFERON®-TB Gold In-Tube Test (QFT-G\\_IT) without documentation of completed treatment or evidence of ongoing treatment of latent tuberculosis (TB) for 30 days. Subjects with active TB infection are excluded.\n4. History of positive PPD, positive QuantiFERON®-TB Gold In-Tube Test (QFT-G\\_IT), or chest x-ray findings indicative of prior TB infection, without documentation of either treatment for TB infection or chemoprophylaxis for TB exposure\n5. Presence of open leg ulcers\n6. Chronic or persistent infection including but not limited to human immunodeficiency virus \\[HIV\\], untreated hepatitis B, listeriosis, TB, or other opportunistic infection). Patients with hepatitis C but without evidence of cirrhosis or significant hepatic dysfunction will be considered for inclusion on a case-by-case basis as will patients with chronic hepatitis B on anti-viral therapy.\n7. Active infection or severe infections requiring hospitalization or treatment with intravenous (IV) antibiotics, IV antivirals, or IV antifungals within 30 days prior to randomization, or oral antibiotics, oral antivirals, or oral antifungals within 14 days prior to randomization\n8. Receipt of a live vaccine within 4 weeks prior to randomization\n9. History of malignancy within the past 5 years other than treated localized carcinoma in situ of the cervix or adequately treated non-metastatic squamous or basal cell skin carcinoma\n10. Any medical condition, which, in the opinion of the investigator, would put the subject at risk by participation in the protocol\n11. Women of childbearing potential who are sexually active and who do not agree to practice one of the following methods of contraception during the duration of the study: condoms, sponge, foams, jellies, diaphragm or intrauterine device; oral or parenteral contraceptives for 2 months prior to study product administration; a vasectomized partner; abstinence.\n12. Pregnant (all women of childbearing potential must have a negative serum pregnancy test) or breastfeeding\n13. Any investigational agent within the earlier of 4 weeks or 5 half-lives prior to randomization\n14. History of drug or alcohol abuse within 6 months prior to randomization\n15. Known allergy or hypersensitivity to any study products\n16. Any psychiatric disorder that prevents the subject from providing informed consent\n17. Inability or unwillingness to follow the protocol.\n18. Unable to undergo MR imaging.",{"count":54,"type":21},8,"INTERVENTIONAL",[57,58],"PHASE1","PHASE2","Patients harboring dolichoectactic vertebrobasilar (DVB) aneurysms are at risk of suffering SAH, ischemic stroke, and\u002For brainstem compression and many patients are not offered invasive treatment due to the futility of existing surgical methods. Consequently, there is demand for development of medical therapy for DVB aneurysms",[25,61,62,63],"Stroke","Vasculitis","Tumor Necrosis Factor-alpha","2026-06-08",{"date":66,"type":38},"2026-06-11",{"date":68,"type":38},"2024-10-01",{"date":70,"type":21},"2028-12",{"name":72,"class":73},"University of California, San Francisco","OTHER",1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":55,"phases":84,"briefSummary":86,"conditions":87,"keywords":90,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100569066","multimodal-biocollection-linked-to-the-french-register-of-intracranial-aneurysms-100569066","NCT06689410","Multimodal Biocollection Linked to the French Register of Intracranial Aneurysms","bCAN","Inclusion criteria for sporadic ICA cases:\n\n* Any adult patient consulting for a definite and typical bifurcation AIC authenticated on MRI and\u002For cerebral arteriography\n* Aneurysm discovered less than a year ago, with initial imaging (MRI and\u002For CTA and DSA) available\n* Written consent obtained for study participation\n* Patient covered by a social security plan\n\nInclusion criteria for index and related cases (familial forms) of intracranial aneurysms (ICA):\n\n* Index case: Any adult patient consulting for a definite and typical bifurcation ICA presenting at least one other case with ICA related (child, parent, brother, sister) detected by MRI with at least one Time of Flight (TOF) sequence.\n* Family relatives: children, parents, brothers, sisters, of legal age, of patients with a family history of definite, typical bifurcation AIC (≥ 4 affected), Screening to be performed using MRI with at least a Time of Flight (TOF) sequence.\n* Written consent to participate in the study\n* Patient and relatives covered by a social security plan\n\nExclusion Criteria:\n\n* Syndromic diagnosis known to cause ICA: Marfan syndrome, OSA with SMAD 3, Elhers Danlos syndrome type II and IV, Autosomal Dominant Cystic Fibrosis, Moya-Moya syndrome\n* AIC with : Dissecting or fusiform, Associated with arteriovenous malformation, Blister-like, Mycotic\n* Cerebral white matter pathology detected on MRI evoking : Col4a1 mutation\n* Patient under guardianship or conservatorship\n* Person under court protection\n* Contraindication to an MRI scan",{"count":83,"type":21},1100,[85],"NA","The purpose of the bCAN study is to create a prospective collection of multimodal data and human samples, linked to the French Intracranial Aneurysm Registry (FRAN).\n\nThe aim of bCAN is to enable risk stratification of ruptured ICAs by redefining \"intracranial aneurysm disease\". The description of genotypically and phenotypically specific subgroups of cases will pave the way for improved patient management based on new diagnostic\u002Fprognostic strategies among AIC carriers, either in a familial context, or at the level of the general population.",[25,88,89],"Brain Aneurysm","Congenital Disease",[91,92,93,94,95],"intracranial aneurysm","phenotype","genetics","imaging","multimodal data","2026-05-26",{"date":98,"type":38},"2026-05-29",{"date":100,"type":38},"2025-03-25",{"date":102,"type":21},"2027-03-25",{"name":104,"class":73},"Nantes University Hospital",26,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":55,"phases":117,"briefSummary":118,"conditions":119,"keywords":121,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":135},"100583158","safety-and-efficacy-of-endovascular-treatment-of-intracranial-aneurysms-with-surpass-elite-with-guardian-flow-diverter-guard-100583158","NCT06872684","Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms With Surpass Elite With GUARDian Flow Diverter (GUARD)","Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms With Surpass Elite With GUARDian Flow Diverter","GUARD","Inclusion Criteria:\n\n1. Age is ≥18 and ≤80 years at the time of consent\n2. Has a single unruptured target intracranial aneurysm (IA) of any size with the following characteristics:\n\n   1. Is located on the internal carotid artery or its branches\n   2. Has a wide neck (wide neck typically defined as neck width ≥ 4 millimeter (mm), or dome to neck ratio ≤ 2.0) or no discernible neck\n   3. Aneurysm is either saccular or fusiform in nature\n3. Has a parent vessel diameter ≥ 3.0 mm to ≤ 6.0 mm at the largest diameter\n4. There is documented risk-benefit of endovascular treatment that outweighs the risks of intracranial aneurysm rupture during the subject's expected lifetime if left untreated.\n\nExclusion Criteria:\n\n1. Has an extradural target aneurysm\n2. Has a target aneurysm in the posterior circulation\n3. Perforator or branch vessel, inclusive of the posterior communicating artery, arises from the target aneurysm body or neck (branches or arteries must arise or connect from the parent vessel separate from the aneurysm or neck to not be excluded from trial)\n4. Has a true bifurcation aneurysm, defined as an aneurysm (saccular or non-saccular) located at a point of vessel bifurcation\n5. Has vessel characteristics, such as severe tortuosity (cavernous Internal Carotid Artery (cICA) Type IV1), stenosis (\\>70%), or morphology that would preclude safe endovascular access or proper deployment of the trial device to the target aneurysm\n6. Received previous treatment for the target aneurysm or parent artery where it would interfere with the placement or proper apposition of the device\n7. Has a medical contraindication to trial or procedure related antiplatelet medications (aspirin, clopidogrel\u002FPlavix, ticagrelor, and heparin), local or general anesthesia, or life-threatening allergy to contrast dye\n8. Has a known severe allergy to nickel, chromium cobalt, tungsten, or platinum\n9. Patients with heparin hypersensitivity, including patients with a previous incident of Heparin-Induced Thrombocytopenia (HIT).\n10. Modified Rankin Score (mRS) assessment is ≥ 3 at pre-procedure exam\n11. Presence of unstable neurological deficit (i.e., worsening of clinical condition in the last 30 days prior to the index procedure)\n12. Subarachnoid hemorrhage occurred within 30 days prior to the index procedure\n13. Major surgery (including previous intracranial implant) either occurred within 30 days prior to the index procedure date or is planned to occur within 120 days following the index procedure date\n14. Has more than one intracranial aneurysm (IA) that requires treatment within 12 months after the index procedure\n15. Received previous intracranial implant associated with the symptomatic or vascular distribution within the past 84 days prior to treatment date\n16. Chronic anticoagulation therapy is ongoing or known coagulopathy exists\n17. Has atrial fibrillation with or without pacemaker.\n18. Has other known serious concurrent medical conditions such as cardiovascular disease (including recent myocardial infarction \\[\\\u003C12 weeks\\], symptomatic congestive heart failure, or carotid stenosis), kidney failure (\\>2.0 mg\u002Fdl serum creatinine), pulmonary disease, uncontrolled diabetes, progressive neurologic disorders, terminal cancer, vasculitis, high risk of ischemic stroke or recent stroke\n19. Has acute life-threatening illness (e.g., acute kidney or heart failure) other than the neurological disease to be treated in this trial\n20. Evidence of active infection at the time of treatment\n21. Life expectancy is less than 5 years due to other illness or condition (in addition to an intracranial aneurysm)\n22. Unable to comply with the trial follow up requirements due to conditions such as dementia or psychiatric problems, active substance abuse, or history of non-compliance with medical advice, as determined by the investigator\n23. Pregnant or breast- feeding women or women who wish to become pregnant during the length of trial participation\n24. Presence of intracranial mass (tumor, except meningioma, abscess, or other infection), non-treated arteriovenous malformation (AVM) in the territory of the target aneurysm\n25. Enrollment in another study involving an investigational product that could confound the outcomes of this trial","80 Years",{"count":116,"type":21},183,[85],"The objective of the Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms with Surpass Elite with GUARDian Flow Diverter (GUARD) trial is to evaluate the safety and efficacy of the Surpass Elite with Guardian Flow Diverter System (FDS) in the treatment of unruptured, wide-neck saccular or fusiform, intracranial aneurysms (IAs) located on the internal carotid artery (ICA) or its branches.",[25,120],"Aneurysm, Intracranial",[122,123,124,125],"Saccular Aneurysm","Fusiform Aneurysm","Unruptured Aneurysm","Flow Diverter","2026-04-06",{"date":128,"type":38},"2026-04-08",{"date":130,"type":38},"2025-06-20",{"date":132,"type":21},"2031-01-31",{"name":134,"class":45},"Stryker Neurovascular",10,{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":144,"enrollmentInfo":145,"targetDuration":4,"studyType":55,"phases":147,"briefSummary":148,"conditions":149,"keywords":4,"overallStatus":155,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":74},"100631325","lymphatic-injury-visualization-in-vascular-surgery-100631325","NCT07499206","Lymphatic Injury Visualization in Vascular Surgery","Visualization and Treatment of Lymphatic Injury During Vascular Surgery Procedures in the Groin: A Pilot Study","LymphFistula-P","Inclusion Criteria:\n\n* adult patients undergoing vascular surgery procedures in the groin\n* signed informed consent for study participation\n\nExclusion Criteria:\n\n* pregnant or lactating women\n* prior groin surgery\n* infected surgical site in the groin\n* necessity for further incisions (e.g. bypass surgery)\n* incapability of judgement or consent","100 Years",{"count":146,"type":21},60,[85],"This study aims to assess a simple intervention: Visualization of lymphatic injury + treatment (in case of detection). This will generate data on the incidence of intraoperative lymphatic injury and the effect of treatment. This data will then hopefully enable a multi-center RCT to generate high level evidence on this matter.",[150,151,152,153,25,154],"Vascular Surgical Procedure","Peripheral Arterial Disease(PAD)","Acute Ischemia","Hemmorhage","Pseudoaneurysm","NOT_YET_RECRUITING","2026-03-23",{"date":158,"type":38},"2026-03-30",{"date":160,"type":21},"2026-04",{"date":162,"type":21},"2027-04",{"name":164,"class":73},"University Hospital, Basel, Switzerland",{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":173,"enrollmentInfo":174,"targetDuration":4,"studyType":55,"phases":176,"briefSummary":177,"conditions":178,"keywords":4,"overallStatus":155,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":74},"100630669","eus-guided-embolization-of-the-visceral-artery-aneurysm-100630669","NCT07490678","EUS-guided Embolization of the Visceral Artery Aneurysm","The Safety and Feasibility of EUS-Guided Embolization for Visceral Artery Aneurysms: A Cohort Study","EUS","Inclusion Criteria:\n\n1. Patients aged 18-60 years diagnosed with VAA by CT, MRI, or EUS.\n2. VAA presenting with any symptoms such as abdominal pain or compression; any asymptomatic VAA located in gastric, gastroepiploic, pancreaticoduodenal, gastroduodenal, mesenteric, or colonic arteries; asymptomatic splenic, renal, hepatic, celiac, jejunal, or ileal artery aneurysms with a diameter \\>2 cm; any asymptomatic VAA with an annual maximum diameter increase \\>0.5 cm\u002Fyear; or female patients of childbearing age with VAA.\n3. Patients who are allergic to iodinated contrast or are pregnant, and thus are unsuitable for endovascular intervention.\n4. VAA that is accessible and identifiable by EUS\n\nExclusion Criteria:\n\n1. Patients with unstable vital signs or those accompanied by major organ dysfunction, severe coagulation disorders (INR \\>1.5), active infection, or cardiopulmonary insufficiency, rendering them unable to tolerate endoscopic examination.\n2. Patients with uncorrectable coagulation disorders (PT-INR \\\u003C1.5 and\u002For fibrinogen \\\u003C120 mg\u002FdL) or uncorrectable thrombocytopenia (platelet count \\\u003C20 × 10⁹\u002FL).\n3. Patients with a known allergy to intravenous anesthetic agents.\n4. Patients who have previously undergone surgical, interventional, or EUS-guided treatment for VAA.\n5. Patients unable to provide informed consent.","60 Years",{"count":175,"type":21},30,[85],"Visceral Artery Aneurysm (VAA) refers to a localized or diffuse dilation or bulging of the arterial wall in the arteries supplying the gastrointestinal tract, liver, spleen, and pancreas (celiac trunk, superior mesenteric artery, inferior mesenteric artery, and their branches), caused by various pathological conditions or injuries. Among these, splenic artery aneurysms (60%) and hepatic artery aneurysms (20%) are the most common. Similar to cerebral aneurysms and aortic aneurysms, visceral artery aneurysms are a serious vascular disease that threatens human life, with an incidence of 0.2% to 2.0% in the population, second only to abdominal aortic aneurysms and iliac artery aneurysms. The main etiologies include atherosclerosis, degeneration of the arterial media, infection, fibromuscular dysplasia, congenital abnormalities, trauma, and arteritis.\n\nThe incidence of visceral artery aneurysms ranges from 0.01% to 0.20%. Although the incidence is relatively low, the rupture rate can be as high as 25%, often leading to hemorrhagic shock or even death. The treatment of VAA primarily includes open surgical procedures such as aneurysm resection and vascular reconstruction, as well as endovascular interventions such as aneurysm embolization and covered stent graft placement. Endovascular embolization is the first-line treatment for VAA. This procedure involves puncturing the femoral artery using the Seldinger technique, advancing a microcatheter near the affected vessel, injecting high-pressure iodinated contrast to visualize the lesion, and then superselecting into the aneurysm or adjacent vessels to embolize the aneurysm or its outflow tract using coils or tissue adhesive. However, X-ray-guided treatment is relatively expensive and involves complex steps. Additionally, for small aneurysms, aneurysms with narrow necks, tortuous vessels, or patients allergic to iodine, surgical resection of VAA may be the only option. Surgical procedures are associated with significant trauma, high costs, and multiple complications.\n\nEndoscopic Ultrasound (EUS) involves an ultrasound probe attached to the tip of an endoscope, allowing imaging and fine-needle aspiration of the pancreas, gastrointestinal tract, posterior mediastinum, and retroperitoneum. Linear EUS can also identify abdominal vessels and blood flow signals via color Doppler. Therefore, after localizing the VAA with EUS, a fine-needle aspiration needle is advanced into the aneurysm. Through the needle tract, a 0.035-inch or 0.018-inch coil is deployed, and tissue adhesive is injected under direct visualization until the aneurysm is completely embolized (Figure 1). This technique has been reported in international literature.",[25],"2026-03-22",{"date":181,"type":38},"2026-03-24",{"date":183,"type":21},"2026-03-05",{"date":185,"type":21},"2027-07-25",{"name":187,"class":73},"Qilu Hospital of Shandong University",{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":197,"conditions":198,"keywords":202,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":74},"100543195","determining-postoperative-recovery-and-the-impact-of-adverse-events-in-neurosurgery-based-on-self-reported-app-based-longitudinal-assessment-100543195","NCT06352710","Determining Postoperative Recovery and the Impact of Adverse Events in Neurosurgery Based on Self-reported, App-based Longitudinal Assessment","Determining Postoperative Recovery and the Impact of Adverse Events in Neurosurgery Based on Self-reported, App-based Longitudinal Assessment - a Collaborative Observational Research Project","Inclusion Criteria:\n\n* Age ≥ 18 years\n* The patient must be able to consent\n* The patient is willing to provide data upon one year after surgery\n* The patient possesses and is capable of using a smartphone (Android or iOS operative systems)\n* The patient has the necessary language and cognitive skills to use the smartphone app\n* The patient is scheduled for one of the defined operations (see above for both spinal and cranial) and in a stable, non-life-threatening situation (admitted to the regular ward or intermediate care unit (IMC))\n* Baseline preoperative SWI and QoL assessment is possible (minimum requirement is one assessment, the latest the day before surgery)\n\nExclusion Criteria:\n\n* Pregnancy\n* Foreseeable difficulties using the smartphone or smartphone app\n* The presence of a condition that hinders the baseline preoperative assessment\n* Health conditions that render inclusion unsafe (e.g., untreated ruptured intracranial aneurysm or congestive heart failure; in general, all patients admitted to the intensive care unit (ICU))",{"count":196,"type":21},400,"Analyzing the impact of surgery and adverse events (AEs) on patients' well-being is of paramount importance as it provides essential information for benefit-risk assessment. Current methods in outcome research are static, resource-intensive and subject to missing-data issues. Moreover, AEs are inconsistently reported using various grading systems that usually do not account for patients' subjective well-being. These are severe drawbacks for outcome research as it hinders monitoring, comparison, and improvement of treatment quality.\n\nThe increasing use of smartphones offers unprecedented opportunities for data collection. The investigators developed a free smartphone application to assess fluctuations of patients' well-being as a result of surgical treatment and possible AEs. The application is installed on each patient's smartphone and collects standardized data at defined timepoints before and after surgery (well-being, AE description and severity).\n\nBy acquiring longitudinal patient-reported outcome before and after neurosurgical interventions, the investigators aim to determine the regular postoperative course for specific surgical procedures, as well as any deviation thereof, depending on the occurrence and severity of AEs. The investigators will evaluate the validity of existing AE classifications and, if necessary, propose a new patient-centered scheme. The investigators hope that this will result in an increase in standardized reporting of patient outcome, and ultimately allow for evidence-based patient information and decision-making.",[199,200,201,25],"Disc Disease","Instabilities Lumbar","Brain Tumor",[203,204,205,206,207,208,209,210],"Outcome","PROMs","App","Neurosurgery","Adverse event","Complication","Quality of life","TDN","2026-03-17",{"date":213,"type":38},"2026-03-19",{"date":215,"type":38},"2023-06-12",{"date":217,"type":21},"2027-12-31",{"name":219,"class":73},"Cantonal Hospital of St. Gallen",{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":224,"acronym":225,"eligibilityCriteria":226,"healthyVolunteers":11,"sex":16,"minAge":227,"maxAge":4,"enrollmentInfo":228,"targetDuration":4,"studyType":55,"phases":229,"briefSummary":230,"conditions":231,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":74},"100577035","evaluation-of-flow-diverter-technology-device-for-intracranial-aneurysm-shield-100577035","NCT06793059","Evaluation of Flow Diverter Technology Device for Intracranial Aneurysm (SHIELD)","SHIELD","Inclusion Criteria:\n\n* Adults (22 years of age or older) with large or giant wide-necked intracranial aneurysms (IAs) in the internal carotid artery from the petrous to the superior hypophyseal segments.\n\nExclusion Criteria:\n\nExclusion Criteria:\n\n* Cannot provide consent or legally authorized representative not available to provide consent Criteria:","22 Years",{"count":135,"type":21},[85],"The Jacobs Institute is participating in a study designed to collect prospective clinical evidence to evaluate the approved use of the Pipeline™ Flex Embolization Device with Shield Technology™ for the endovascular treatment of adults (22 years of age or older) with wide-necked intracranial aneurysms",[25],"2026-03-06",{"date":234,"type":38},"2026-03-10",{"date":236,"type":38},"2025-01-01",{"date":238,"type":21},"2027-01-01",{"name":240,"class":73},"Jacobs institute",{"id":242,"slug":243,"hasResults":11,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":247,"eligibilityCriteria":248,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":251,"conditions":252,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":74},"100276489","standardized-long-term-follow-up-of-patients-after-endovascular-embolization-of-a-brain-aneurysm-100276489","NCT02878967","Standardized Long Term Follow-up of Patients After Endovascular Embolization of a Brain Aneurysm","Standardized Long Term Follow-up of Patients After Endovascular Embolization of a Brain","ANENDOVASC","Inclusion Criteria:\n\n* curative embolization of a brain aneurysm\n* age \\>18 years old\n\nExclusion Criteria:\n\n* none",{"count":250,"type":21},2000,"The time-frame and the follow-up elements after embolization of brain aneurysm are not standardized. Therefore, few reliable follow-up data are available for these patients.\n\nThis study aims at collecting standardized long term data for these patients, in order to assess the occurence of aneurysm recanalization and particularly those requiring another intervention on the aneurysm.",[25],"2026-01-21",{"date":255,"type":38},"2026-01-22",{"date":257,"type":38},"2015-11-25",{"date":259,"type":21},"2040-11-24",{"name":261,"class":262},"Fondation Ophtalmologique Adolphe de Rothschild","NETWORK",{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":269,"eligibilityCriteria":270,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":271,"targetDuration":272,"studyType":22,"phases":4,"briefSummary":273,"conditions":274,"keywords":283,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":294},"100404373","panther-study-of-terumo-aortic-knitted-and-woven-grafts-and-cardiovascular-patches-100404373","NCT04545502","PANTHER Study of Terumo Aortic Knitted and Woven Grafts, and Cardiovascular Patches","A Prospective and Retrospective, Multi-Centre, Post-Market, Non-Interventional Study of Terumo Aortic Knitted and Woven Grafts, and Cardiovascular Patches","PANTHER","Inclusion Criteria:\n\n* Patients must meet all of the following inclusion criteria in order to be eligible for inclusion in the study:\n\nAll Patients:\n\n* Patient meets the minimum age as per local regulations at time of consent\n* Patient requires treatment with study device(s) according to the IFU(s)\n* Patient is willing and able to comply with all SOC procedures and study visits\n* Patient or their legally authorised representative (LAR) has given written informed consent to participate in study, including consent to collect data retrospectively\n\n  * For prospective emergency patients, retrospective consent is permissible\n  * For retrospective patients who are deceased at time of enrollment, local EC regulations relating to consent process should be followed.\n\nRetrospective Patients only:\n\n* Patient has a minimum of 1 year post-operative follow-up data available, or complete data to death.\n* Patient implant date is no more than 5 years prior to study start date.\n\nExclusion Criteria:\n\n* Any patient who meets any of the following exclusion criteria will be excluded from participation in the study:\n\n  * Patient is unable or unwilling to comply with the SOC procedures or follow-up regime\n  * Patient is contraindicated per the device IFU\n  * Patient has any other medical, social or psychological problems that in the opinion of the investigator preclude them from receiving this treatment and the procedures and evaluations pre- and post-procedure",{"count":250,"type":21},"10 Years","The purpose of this registry is to collect safety and performance data on all commercially available Terumo Aortic knitted and woven grafts, and cardiovascular patches in standard clinical practice.\n\nData will be collected both retrospectively and prospectively.",[25,275,276,277,278,279,280,281,282],"Dissection","Aortic Root Aneurysm","Aortic Root Dissection","Carotid Artery Injuries","Aortic Arch","Bypass Extremity Graft","Occlusive Vascular Disease","Aortic Diseases",[284],"Vascular Surgery","2025-05-28",{"date":287,"type":38},"2025-06-03",{"date":289,"type":38},"2021-02-17",{"date":291,"type":21},"2037-01",{"name":293,"class":45},"Vascutek Ltd.",31,{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":4,"eligibilityCriteria":301,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":302,"targetDuration":304,"studyType":22,"phases":4,"briefSummary":305,"conditions":306,"keywords":311,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":325},"100555113","post-market-registry-for-gore-tag-thoracic-branch-endoprosthesis-100555113","NCT06507865","Post Market Registry for GORE® TAG® Thoracic Branch Endoprosthesis","Characterization of Mid-term Post Market Clinical Follow Up of GORE® TAG® Thoracic Branch Endoprosthesis Facilitated Aortic Arch and Descending Aorta Intervention","Inclusion Criteria:\n\nPatient or legally authorized representative (LAR) provides written authorization and\u002For consent per institution and geographical requirements Patient has been or is intended to be treated with an eligible registry device Patient is age ≥ 18 years at time of informed consent signature.\n\nExclusion Criteria:\n\nPatient who is, at the time of consent, unlikely to be available for standard of care (SOC) follow-up visits as defined by the site's guidelines and procedures.\n\nPatient with exclusion criteria required by local law. Patient is currently enrolled in or plans to enroll in any concurrent drug and\u002For device study within 12 months of Together Registry enrollment. Subjects cannot be enrolled in another Together Registry module protocol.",{"count":303,"type":21},200,"2 Years","The goal of this observational study is to collect mid-term post-market clinical follow-up data of GORE® TAG® Thoracic Branch Endoprosthesis used according to the standard medical practice in patients presenting with vascular disease. This registry aims to answer questions related to the efficacy and safety of GORE® TAG® Thoracic Branch Endoprosthesis.",[25,307,308,309,310],"Dissection, Aortic","TAA Thoracoabdominal Aortic Aneurysm","Thoracic Aortic Aneurysm","Transection Aorta",[312,25,275,313,314,315],"TEVAR","Aorta","Endovascular stent graft","Thoracic branch endoprosthesis","2025-05-05",{"date":318,"type":38},"2025-05-09",{"date":320,"type":38},"2025-02-20",{"date":322,"type":21},"2031-04",{"name":324,"class":45},"W.L.Gore & Associates",20,{"id":327,"slug":328,"hasResults":11,"nctId":329,"briefTitle":330,"officialTitle":331,"acronym":4,"eligibilityCriteria":332,"healthyVolunteers":11,"sex":16,"minAge":333,"maxAge":144,"enrollmentInfo":334,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":336,"conditions":337,"keywords":338,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":74},"100534191","arch-size-study-for-anatomical-variations-100534191","NCT06235619","Arch Size Study for Anatomical Variations","CT Anatomical Characteristics of the Aortic Arch in Subjects With or Without Aneurysms Requiring Treatment","Inclusion Criteria:\n\nall patients with aortic arch CT scan at investigating centers\n\nExclusion Criteria:\n\nnone","0 Years",{"count":335,"type":21},500,"The aortic arch with a common origin of the innominate and left carotid artery (CILCA) prevalence in the general population is 13.6%. Its reputation as a benign anatomical variant has been ultimately shattered by further studies that identified the CILCA arch as a potential marker for thoracic aortic disease (TAD) The aim of this work is to report the CT anatomical characteristics of the aortic arch in subjects with or without aneurysms requiring treatment, in 5 major European cardiovascular centers.",[279,25,307],[339,340,341],"Aortic arch","Bovine arch","Thoracic aortic disease","2025-04-30",{"date":344,"type":38},"2025-05-02",{"date":346,"type":38},"2024-09-01",{"date":348,"type":21},"2026-12-01",{"name":350,"class":73},"IRCCS San Raffaele",{"id":352,"slug":353,"hasResults":11,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":357,"eligibilityCriteria":358,"healthyVolunteers":359,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":360,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":362,"conditions":363,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":372,"locationsCount":74},"100532413","an-observational-study-on-theaccuracy-of-whole-body-magnetic-resonance-imaging-wb-mri-screeningto-predict-clinically-significant-diagnoses-in-general-population-subjects-interested-in-proactive-and-advanced-general-preventive-healthcare-100532413","NCT06212479","An Observational Study On TheAccuracy Of Whole-Body Magnetic Resonance Imaging (Wb-Mri) ScreeningTo Predict Clinically Significant Diagnoses In General Population Subjects Interested In Proactive And Advanced General Preventive Healthcare.","A Multi-Site Prospective, Single-Arm, Observational Study On The Accuracy Of Whole Body Magnetic Resonance Imaging (Wb-Mri) Screening To Predict Clinically Significant Diagnoses In General Population Subjects Interested In Proactive And Advanced General Preventive Healthcare.","Hercules","Inclusion Criteria:\n\n* Each subject MUST:\n\n  * Be\\>=18 years of age at the time of enrollment.\n  * Be able to read and understand provided procedural information for the study;\n  * Be able and willing to follow all study procedures including proper breathing and body movement minimization while within the WB-MRI system;\n  * Be willing and able to provide required clinical, demographic, medical history, and concomitant medications information;\n  * Be able to provide financial payment in advance for reimbursement of the cost of the WBMRI acquisition procedure and interpretation;\n  * Complete all required consent procedures.\n\nExclusion Criteria:\n\n* Harbor within their bodies contraindicated medical devices including, but not limited to, implanted pacemakers, intracranial aneurysm clips, cochlear implants, drug infusion pumps, neurostimulators, bone growth stimulators, certain intrauterine contraceptive devices, non- MRI safe metals, etc.;\n\n  * Self-certify that they are pregnant;\n  * Be seeking to undergo WB-MRI as a subject in this study in lieu of other covered dedicated diagnostic imaging evaluations when such covered procedures represent more appropriate or standard-of-care procedures by context-specific clinical indication;\n  * Be an employee of the study site or the sponsor;\n  * Have a medical condition or serious intercurrent illness, or other circumstance that, in the Investigator's judgment, could jeopardize the candidate's safety as a study subject, or that could interfere with study objectives.",true,{"count":361,"type":21},100000,"This is a prospective, single-arm, observational study capturing data from whole-body magnetic resonance imagining (WB-MRI) from up to 100,000 male and female subjects 18 years of age or older recruited at multiple clinical sites within the United States. Study subjects must meet a set of inclusion and exclusion criteria. Potential subjects arriving at the study sites will be evaluated for enrollment. It is the Principal Investigator's (PI) responsibility to enroll only subjects who satisfy the inclusion\u002Fexclusion criteria. Recruitment can occur by subject presentation at the sites for elective standard screening, word-of-mouth, flyers, healthcare professional (HCP) referrals, advertisement online, or any other means, subject to approval by the associated institutional review board (IRB) or ethics committee (EC) when applicable.",[364,365,25,366],"Cancer","Metabolic Disease","Neurologic Disorder","2025-04-28",{"date":342,"type":38},{"date":370,"type":38},"2024-05-17",{"date":291,"type":21},{"name":357,"class":45},{"id":374,"slug":375,"hasResults":11,"nctId":376,"briefTitle":377,"officialTitle":377,"acronym":378,"eligibilityCriteria":379,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":114,"enrollmentInfo":380,"targetDuration":381,"studyType":22,"phases":4,"briefSummary":382,"conditions":383,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":392,"locationsCount":394},"100506922","sealme-saccular-endovascular-aneurysm-lattice-system-multicenter-enrollment-global-registry-100506922","NCT05880680","SEAL™ME: Saccular Endovascular Aneurysm Lattice System Multicenter Enrollment Global Registry","SEAL™ME","Inclusion Criteria:\n\n1. 18 to 80 years of age at the time of screening.\n2. Unruptured aneurysm requiring endovascular treatment suitable for SEAL device and meet the AHA guidelines for management of unruptured aneurysm.5 If there is evidence of an additional aneurysm requiring treatment, the secondary aneurysm must also be treatable using a SEAL™ System Device, either during a single procedure or consecutive procedures.\n\n   No additional preplanned implanted devices are permissible except for as medically required for patient safety during the procedure.\n3. Ruptured aneurysm\n\n   1. Ruptured aneurysms may be included according to the following criteria: The subject is neurologically stable with no seizure at the onset of the SAH, not requiring EVD placement prior to inclusion.\n   2. Hunt and Hess scale of 3 or less at the time of treatment.\n   3. Modified Disability Scale (mRS) of ≤2 prior to presentation or aneurysm rupture.\n   4. Meet the AHA guidelines for management of ruptured aneurysm.6\n4. The index intracranial aneurysm (IA) to be treated must include the following features:\n\n   1. Aneurysm features suitable for endovascular treatment with an intrasaccular device per the treating interventionist.\n   2. Saccular morphology.\n   3. Located at a bifurcation, terminus, or sidewall in the anterior or posterior circulation.\n   4. 2.5 mm-20 mm in dome diameter.\n   5. Wide-neck aneurysm with neck size ≥ 4mm or Dome-to-Neck (DN) ratio \\\u003C 2.\n5. Aneurysm treatment does not require the preplanned use of any additional implanted devices.\n6. Subject is able to maintain compliance with all aspects of screening, evaluation, treatment, and post-procedure follow-up schedule.\n7. Baseline pre-procedure mRS of 0-2 for unruptured aneurysm and 0-2 prior to the SAH for the ruptured aneurysms.\n8. Ability to obtain written informed consent from subject or legally authorized representative in SAH subjects prior to the initiation of any study procedures.\n\nExclusion Criteria:\n\n1. Aneurysm features unsuitable for endovascular treatment with an intrasaccular device such as fusiform, dissecting pseudo aneurysm, or mycotic aneurysm.\n2. Aneurysms smaller than 2.5 mm and larger than 20 mm in dome width.\n3. Inability to access target aneurysm with microcatheter due to intracranial atherosclerosis, proximal or intracranial vessel tortuosity or poor aneurysm angle take-off.\n4. Patients with two 360 degrees loops in the carotid or vertebral arteries.\n5. Presence of vascular disease or other vascular abnormality that could prohibit access to index aneurysm such carotid stenosis or diminished caliber of the target artery.\n6. Clinical, angiographic, or CT evidence of CNS arterial vasculitis, Moyamoya disease, intracranial tumor (except small meningioma), or any other intracranial vascular malformations.\n7. Patients with high risk for recurrent ischemic stroke due to previous history of ischemic stroke symptoms such as transient ischemic attacks (TIAs), minor, or major strokes within the past 60 days. Other stroke risk factors such as intracranial stenosis or atrial fibrillation.\n8. Patients with hemodynamic or medical compromise due to medical comorbidities such as severe unstable congestive heart failure (ejection fraction \\\u003C30%) or severe COPD requiring home oxygen.\n9. Modified Rankin Scale (mRS) score of \\> 2 prior to presentation.\n10. Target index aneurysm that has been previously treated and contains devices, implants, or coils that could interfere with correct SEAL™ device placement.\n11. Subject is pregnant or a lactating female (For females of child-bearing potential, a positive pregnancy test within 7 days of the day of procedure or refusal to use a medically accepted method of birth control for the duration of the study.\n12. Currently on anticoagulation therapy or has a known blood dyscrasia, coagulopathy, or hemoglobinopathy.\n13. Currently enrolled in another investigational study or post-market study that could affect the safety and efficacy of aneurysm treatment or interfere with the study follow-up schedule.\n14. Presence of an acute life-threatening illness requiring treatment.\n15. Life expectancy of \\\u003C1 year.\n16. Subject has an uncontrolled co-morbid medical condition, that would adversely affect participation in the study.\n17. Patient with chronic kidney disease (and not on dialysis) with creatinine \\> 2.0.\n18. Subject is a prisoner or member of other vulnerable population.\n19. Subject that is in the opinion of the treating interventionalist is not suitable for the study.\n\n    * Sensitivity to nickel is not specifically excluded, Galaxy Therapeutics, Inc (GTI) performed ASTM F2129 testing recommended by the FDA in its 2015 and 2019 guiding documents. GTI results from the testing indicated that SEALTM meets the acceptance criteria that there is a high probability that the margin of safety against pitting (Eb-Er) is 200mV or higher, therefore, with high confidence, no further testing is required. The IFU contains the following precaution: \"For patients with known hypersensitivity or allergic reaction to the implant components such as titanium or to nickel, use of the SEALTM System may lead to allergic reaction and user should counsel the patient on the device components\".",{"count":303,"type":21},"5 Years","Prospective, international, single-arm, multicenter, registry study. Patients presenting with evidence of Wide Neck unruptured or ruptured intracranial aneurysm (≤ 20 mm in widest diameter) requiring treatment will be enrolled into the study and treated using the SEAL™ System.",[25,384],"Aneurysm, Ruptured","2025-04-01",{"date":387,"type":38},"2025-04-04",{"date":389,"type":38},"2023-10-09",{"date":391,"type":21},"2030-06-15",{"name":393,"class":45},"Galaxy Therapeutics INC",4,{"id":396,"slug":397,"hasResults":11,"nctId":398,"briefTitle":399,"officialTitle":400,"acronym":4,"eligibilityCriteria":401,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":402,"enrollmentInfo":403,"targetDuration":4,"studyType":55,"phases":405,"briefSummary":406,"conditions":407,"keywords":409,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":413,"lastUpdatePostDateStruct":414,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":420,"locationsCount":74},"100504240","phase-2-tocilizumab-and-tofacitinib-in-the-treatment-of-vascular-behets-syndrome-100504240","NCT05845723","Tocilizumab and Tofacitinib in the Treatment of Vascular Behçet's Syndrome","Efficacy and Safety of Tocilizumab and Tofacitinib in the Treatment of Patients With Vascular Behçet's Syndrome","Inclusion Criteria:\n\n1． Understand and voluntarily sign an informed consent form prior to any study-related assessments\u002Fprocedures being conducted.\n\n2\\. Male and female subjects aged 18-65 years.\n\n3． Fulfill the 2013 International Classification Criteria for Behcet's Disease (ICBD).\n\n4． Patients with aneurysmal dilatation\u002Faneurysm of the descending aorta and\u002For peripheral arteries confirmed by ultrasonography and\u002For computed tomography angiography (CTA).\n\n5\\. Elevated acute phase reactants ESR and hs-CRP.\n\nExclusion Criteria:\n\n1. Cardiovascular manifestations that cannot be distinguished from giant cell arteritis, Burger's disease, or atherosclerotic aneurysm; infectious aneurysm;\n2. Other active organ involvement related to BS that requires intensified immunosuppressive treatment, including gastrointestinal ulcers, uveitis, and parenchymal neurological involvement;\n3. Patients with severe aneurysms requiring emergency intervention surgery; patients with elective surgery indications require the consensus between rheumatologists and vascular surgeons to determine inclusion or exclusion.\n4. Severe organ dysfunction, including ALT, AST, and TBIL exceeding the upper limit of normal by more than 2 times, serum creatinine ≥ 133 mmol\u002FL, white blood cell count \\\u003C 3×10\\^9\u002FL, ANC \\\u003C 2×10\\^9\u002FL, hemoglobin \\\u003C 80g\u002FL, platelet count \\\u003C 100×10\\^9\u002FL;\n5. Active infection such as active tuberculosis, hepatitis B or C, syphilis, chronic EBV infection, persistent or severe bacterial or viral infection;\n6. Primary or secondary immunodeficiency;\n7. Malignant tumor;\n8. Use of immunosuppressants such as Cyclosporin A (CsA), Azathioprine (AZA), Tacrolimus (TAC), Mycophenolate Mofetil (MMF), or Cyclophosphamide (CTX) within 1 month;\n9. Use of biologics\u002Fsmall molecule drugs within 5 half-lives (baricitinib within 10 days; etanercept within 4 weeks; infliximab within 8 weeks; adalimumab, golimumab, ustekinumab, and abatacept within 10 weeks, secukinumab within 6 months, and previously use of tocilizumab and tofacitinib);\n10. Pregnant, lactating, or planning a recent pregnancy;\n11. Subjects who do not agree to or are unable to comply with regular visits.","65 Years",{"count":404,"type":21},81,[58],"This project aims to evaluate the efficacy and safety of the combination of glucocorticoids with tocilizumab or tofacitinib, compared to the traditional combination of glucocorticoids with cyclophosphamide in the treatment of vascular Behçet's syndrome.",[25,408],"Behcet Syndrome, Vascular Type",[410,411,412],"Tocilizumab","Tofacitinib","Vascular Behçet's Syndrome","2024-08-16",{"date":415,"type":38},"2024-08-19",{"date":417,"type":38},"2023-06-01",{"date":419,"type":21},"2027-06-01",{"name":421,"class":73},"Peking Union Medical College Hospital",{"id":423,"slug":424,"hasResults":11,"nctId":425,"briefTitle":426,"officialTitle":427,"acronym":4,"eligibilityCriteria":428,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":114,"enrollmentInfo":429,"targetDuration":4,"studyType":55,"phases":430,"briefSummary":431,"conditions":432,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":436,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":74},"100530681","registration-trial-of-the-intracranial-visualized-stent-for-the-wide-necked-intracranial-aneurysmsrebridge-100530681","NCT06189950","Registration Trial of the Intracranial Visualized Stent for the Wide-necked Intracranial Aneurysms:REBRIDGE","a Prospective, Multi-center, Open-label, Non-inferiority, Randomized, Controlled Registration Trial of the Intracranial Stent for the Treatment of Intracranial Aneurysms: Rebridge","Inclusion Criteria:\n\n* At the time of signing the informed consent form(ICF), the applicant shall be male or non-pregnant female, aged 18 to 80 years； Target aneurysms was diagnosed as intracranial widenecked saccular aneurysms by DSA\u002FCTA\u002FMRA； The target aneurysm should be suitable for stentassisted coiling surgery and could be treated through one operation； Subject or its legal representative should be able to understand the purpose of this study, also agree to comply with protocol and sign the informed consent form voluntarily.\n\nExclusion Criteria:\n\n* Aneurysms unsuitable for stent-assisted coiling (i.e. aneurysm necks ≤ 4 mm and or body-to-neck ratio ≥ 2)； The distal diameter of the aneurysm-carrying artery is outside the range of application of the investigational device; mRS score ≥3; Subjects with recurrent aneurysms treated by stent-assisted coiling; Multiple aneurysms and all aneurysms requiring intervention; Subjects with ruptured aneurysms \\\u003C30 days ; Significant stenosis (≥50%) or occlusion of parent artery; Subjects unsuitable for anaesthesia or endovascular surgical treatment, e.g. major diseases of the heart, lungs, liver, spleen and kidneys, brain tumours, severe active infections, disseminated intravascular coagulation, and a history of severe mental illness; Subjects undergoing major surgical procedures (e.g. tumour resection, surgery of vital organs, etc.) within 30 days prior to signing the informed consent form, or scheduled to undergo such procedures within 60 days after signing the informed consent form; Subjects with morphologies or pathologies that may interfere with device use, including, but not limited to: carotid artery coarctation, vasculitis, aortic coarctation, limited vascular access (e.g., severe intracranial vascular tortuosity, severe intracranial vasospasm unresponsive to medication, other anatomical or clinical pathologies that would prevent access to the device); Contraindications to stenting, including but not limited to: contraindication to DSA, allergy or intolerance to contrast media, allergy or intolerance to antiplatelet and anticoagulant medications required for treatment, allergy to nickel-titanium and platinum-tungsten and platinum-iridium alloys; Pregnant or breastfeeding women; Life expectancy less than 12 months; Subject participation in other drug or device studies that do not meet endpoints",{"count":303,"type":21},[85],"This trial was designed as a prospective, multicentre, open, non-inferiority, randomised controlled clinical trial, with the control devices being MicroVention's LVIS Intraluminal Support Device and LVIS Jr. Intraluminal Support Device. Approximately 200 subjects with intracranial aneurysms would be enrolled for stent-assisted coiling embolisation according to the inclusion and exclusion criteria specified in this trial protocol. Subjects were evaluated by mRS preoperatively, at the time of device implantation, at the time of discharge from the hospital, at 1 month (±7 days) postoperatively, at 6 months (±30 days) postoperatively, and at 12 months (±60 days) postoperatively; subjects would underwent DSA imaging at surgery and at 6 months (±30 days) postoperatively, and MRA or DSA imaging at 12 months (±60 days) postoperatively. Unplanned follow-up of the subjects would performed when necessary, and data would be recorded to evaluate the safety and efficacy of intracranial artery stent for stent-assisted coiling embolisation for the treatment of intracranial aneurysms.",[433,25,434],"Brain Diseases","Intracranial Aneurysm","2024-01-02",{"date":437,"type":38},"2024-01-05",{"date":439,"type":38},"2023-10-30",{"date":441,"type":21},"2026-10-30",{"name":443,"class":45},"MicroPort NeuroTech Co., Ltd."]